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Purpose: Following the publication of 5-year agalsidase alfa enzyme replacement therapy
(ERT) outcomes data from the Fabry Outcome Survey (FOS), 10-year data were analyzed.
Patients and methods: FOS (ClinicalTrials.gov identifier: NCT03289065) data (April
2001 to August 2018) were retrospectively analyzed. Estimated glomerular filtration rate
(eGFR) and left ventricular mass indexed to height (LVMI) were analyzed after treatment
start (baseline) for patients with ≥3 measurements, including baseline and year 10.
Results: Median (range) age (years) of the evaluable treated renal cohort at treatment start
was 48.8 (17.9–67.3) for females (n=62), 34.4 (18.0–66.8) for males (n=90). With eGFR ≥60
mL/min/1.73 m2 at baseline, mean (95% CI) rate of eGFR change (eGFR/year) over 10 years
was relatively stable in females (n=52; −0.55 [−1.12, +0.01]) and slightly declined in males
(n=79; −1.99 [−2.45, −1.54]). With impaired kidney function (eGFR <60 mL/min/1.73 m2) at
baseline, mean (95% CI) eGFR/year was stable in females (n=10; −0.14 [−1.43, +1.15]) and
slightly declined in males (n=11; −2.79 [−4.01, −1.56]) over 10 years. Median (range) age
(years) of the evaluable treated cardiac cohort at treatment start was 46.7 (3.7–67.3) for
females (n=34), 28.2 (4.0–54.2) for males (n=35). With left ventricular hypertrophy (LVH;
LVMI >48 g/m2.7 in females, >50 g/m2.7 in males) at baseline, mean (95% CI) LVMI/year
slightly increased over 10 years in females (n=18; +1.51 [+0.91, +2.12]) and males (n=14;
+0.87 (+0.19, +1.55). Without LVH at baseline, mean (95% CI) LVMI/year was stable in
females (n=16; +0.52 [−0.13, +1.17]) and males (n=21; +0.57 [+0.02, +1.13]) over 10 years.
Conclusion: Agalsidase alfa-treated patients with 10-year FOS data and preserved kidney
function and/or normal LVMI at baseline remained largely stable; those with decreased
kidney function or LVH at baseline experienced modest declines in renal function and/or
increases in LVMI.
Keywords: agalsidase alfa, enzyme replacement therapy, Fabry disease, cardio-renal
outcomes
Introduction
Fabry disease is a rare X-linked disorder caused by the lack of the lysosomal enzyme
α-galactosidase A, which affects glycosphingolipid metabolism. Consequences of this
progressive disease include neuropathic pain, angiokeratoma, progressive renal
damage leading to kidney failure, cardiomyopathy, arrhythmia, transient ischemic
attacks and/or strokes, and reduced lifespan.1 The advent of enzyme replacement
therapy (ERT) in 2001 offered the potential for improved outcomes in patients with
Fabry disease as well as improving pain scores and measures of patient quality of
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life.2 Evidence suggests that improved outcomes may be
particularly true when treatment is initiated early, before
irreversible damage has occurred in target organs such as
the kidney and heart.3–7 Fabry-specific therapy is used
together with ancillary therapies for patients with renal or
cardiac disease, such as angiotensin receptor blockers,
angiotensin-converting enzyme inhibitors, and interventions
aimed at arrhythmia and congestive heart failure.7
The Fabry Outcome Survey (FOS), initiated by Shire
(now part of Takeda) in 2001, collects long-term data from
patients in 24 countries on the natural history of Fabry
disease and the safety and efficacy of treatment with
agalsidase alfa.8 A previous evaluation of FOS data from
patients who had received 5 years of agalsidase alfa ERT
showed this was associated with reduced morbidity and
mortality.9 The current objective was to perform an addi-
tional retrospective analysis of data extracted from FOS in
August 2018 to assess cardiac and renal outcomes in




The FOS all treated 10-year cohort (n=388) comprised all
children and adults followed in FOS who initiated agalsi-
dase alfa ERT 0.2 mg/kg intravenously every other week
either before or during entry into FOS and received it for a
minimum of 10 years before data extraction on August 3,
2018. Of 350 patients (n=38 missing) in the all-treated
cohort, we identified that 197 (56.3%) patients within the
cohort were carrying mutations related to classic Fabry
disease and 35 (10.0%) patients were carrying mutations
related to late-onset Fabry disease; 118 (33.7%) patients
were of unknown phenotype.
The FOS evaluable treated cohort (n=363) was defined
as the subset of patients who did not receive other ERT
prior to FOS entry, had a known agalsidase alfa ERT start
date and did not have a kidney transplant or receive
dialysis before the start of treatment; this cohort included
44 pediatric (<18 years of age) and 319 adult (≥18 years of
age) patients at FOS entry, and 53 pediatric and 310 adult
patients at ERT start. Patients were excluded if they
received other ERT before FOS entry (n=11) or had
begun dialysis or had a kidney transplant prior to ERT
initiation (n=14; Figure 1).
The FOS evaluable treated renal cohort (n=152; all
adults except 1 pediatric patient at FOS entry but no
pediatric patients at FOS extract) comprised patients
from the evaluable treated cohort with complete longitu-
dinal data, i.e. those who had ≥3 available estimated
glomerular filtration rate (eGFR) measurements after
ERT start, including the baseline and year 10 time points
(Figure 1). The FOS evaluable treated cardiac cohort
(n=69; all adults except 10 pediatric patients at FOS
entry and 1 pediatric patient at FOS extract) included
patients from the evaluable treated cohort with complete
longitudinal data, i.e. patients with ≥3 available left ven-
tricular mass indexed to height (LVMI) measurements
after ERT start, including the baseline and year 10 time
points (Figure 1).
Of the patients excluded from the evaluable treated
cohorts, 3 patients were excluded from the renal and
cardiac cohorts due to switching to another treatment
(type not specified; as entered by the investigator as free
text) before their 10-year data could be collected.
FOS (ClinicalTrials.gov identifier: NCT03289065) has
been approved by the ethics institutional review boards of
participating centers (Supplemental File). Further, this reg-
istry was compliant with relevant global and local regula-
tions and best practices. Good Pharmacoepidemiological
Practice, Good Research for Comparative Effectiveness
principles, and the relevant principles of the International
Conference on Harmonisation Good Clinical Practice
(ICH GCP) guidelines (ICH E6) were followed as appro-
priate for an observational registry. All participants gave
written informed consent.
Assessments
eGFR was calculated only in patients aged ≥18 years at the
time of assessment, using serum creatinine level and an equa-
tion derived from the Modification of Diet in Renal Disease
study.10 LVMI was calculated using the Devereux formula
from measurements obtained by echocardiography.11
Left ventricular hypertrophy (LVH) was defined as LVMI
>48 g/m2.7 in females and LVMI >50 g/m2.7 in males.12,13
LVMI slopes over 10 years were analyzed by sex and base-
line LVH status, and left ventricular posterior wall thickness
in diastole (PWTD) slopes over 10 years were analyzed by
sex and baseline eGFR <60 or ≥60 mL/min/1.73 m2.
Statistical Analysis
The statistical analysis was performed using SAS® soft-
ware version 9.3 (SAS Institute Inc., Cary, NC, USA).
Descriptive statistics were calculated for demographic
and outcome data. For continuous variables, 95%
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confidence intervals (CIs) for means were computed
using t-distribution. Average slope estimates for renal
and cardiac parameters, together with standard errors
(SEs) and 95% CIs, were calculated using a mixed
model with random intercept and slope, without any
assumptions on the within-patient covariance structure
(unstructured covariance matrix).
Mixed models for eGFR and LVMI included time from
treatment start as covariate, sex and baseline renal (eGFR
<60 or ≥60 mL/min/1.73 m2) or cardiac (LVH or no LVH)
status as factors, and all corresponding interactions. Mixed
model for PWTD included time from treatment start, sex,
baseline eGFR level (<60 or ≥60 mL/min/1.73 m2), and all
interactions. In evaluable treated cardiac cohort patients
with baseline eGFR >90 mL/min/1.73 m2 and urinary
protein <0.5 g/day, the model for eGFR included time
from treatment start as covariate, sex as a factor, and
interaction of sex with time variable.
Results
Evaluable Treated Renal Cohort
The evaluable treated renal cohort consisted of 152
patients: 62 females with a median (range) age at treat-
ment start of 48.8 (17.9–67.3) years and 90 males with a
median (range) age at treatment start of 34.4 (18.0–66.8)
years (Table 1). The median (range) time from treatment
start to data extraction from FOS was 12.5 (10.1–17.1)
years in females and 14.4 (10.1–18.4) years in males
(Table 1). Use of angiotensin-converting enzyme inhibi-
tors and/or angiotensin receptor blockers was recorded in
41 of 62 (66.1%) females and 73 of 87 (83.9%) males
(Table 1). Decreased kidney function (stage 3 or 4 chronic
kidney disease, as patients on dialysis or having received a
renal transplant were excluded) at baseline, defined as
eGFR <60 mL/min/1.73 m2, was seen in 10 of 62
(16.1%) females and 11 of 90 (12.2%) males. Baseline
urinary protein data were available for 115 of 152 (76%)
Figure 1 Flow diagram of participants included in the evaluable treated renal cohort and the evaluable treated cardiac cohort.
Abbreviations: eGFR, estimated glomerular filtration rate; ERT, enzyme replacement therapy; FOS, Fabry Outcome Survey; LVMI, left ventricular mass index.
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patients in the evaluable treated renal cohort and indicated
urinary protein ≥1.0 g/24hrs was present in 3 of 45 (6.7%)
females and 9 of 70 (12.9%) males (Table 1).
The mean (95% CI) eGFR measurements (mL/min/1.73
m2) at baseline and year 10, respectively,were 80.4 (75.8, 85.0)
and 79.1 (74.1, 84.0) in females and 95.0 (88.8, 101.2) and 77.
5 (70.1, 84.9) in males (Figure 2). Stratification by baseline
renal function (Figure 3) showed that patients with eGFR ≥60
mL/min/1.73 m2 at baseline had a relatively stable mean (95%
CI) eGFR slope (mL/min/1.73 m2/year) of −0.55 (−1.12,
+0.01) for females (n=52) throughout the 10-year treatment
period and a small negative slope for males (n=79) of −1.99
(−2.45, −1.54). Among those with impaired kidney function
(eGFR <60 mL/min/1.73 m2) at baseline, the mean (95% CI)
eGFR slope (mL/min/1.73 m2/year) throughout the 10-year
treatment period for females (n=10)was stable at−0.14 (−1.43,
+1.15) and showed a modest decline for males (n=11), −2.79
(−4.01, −1.56). For the renal cohort (n=152), blood pressure
valueswere available for 136 patients at baseline; however, the
follow-up data for blood pressure were missing for many
patients meaning that a blood pressure change could not be
adequately analyzed.
Evaluable Treated Cardiac Cohort
The evaluable treated cardiac cohort consisted of 69 patients:
34 females with a median (range) age at treatment start of
46.7 (3.7–67.3) years and 35males with amedian (range) age
at treatment start of 28.2 (4.0–54.2) years (Table 1). The
median (range) time from treatment start to data extraction
from FOS was 12.8 (10.1–16.5) years in females and 14.3
(10.2–17.1) years in males (Table 1). Baseline LVH was
present in 18 (52.9%) females and 14 (40.0%) males
(Table 1).
The mean (95% CI) LVMI measurements (g/m2.7) at
baseline and year 10, respectively, were 52.2 (46.3, 58.1)
and 58.8 (48. 7, 68.9) in females and 49.1 (43.3, 54.9) and
52.0 (43.2, 60.8) in males (Figure 4).
Stratification by the presence or absence of LVH at base-
line (Figure 5) showed that in patients without LVH at base-
line, cardiac mass remained stable in females and in males;
the mean (95%CI) LVMI slopes (g/m2.7/year) throughout the
10-year treatment period were +0.52 (−0.13, +1.17) for
females (n=16) and +0.57 (+0.02, +1.13) for males (n=21).
Among those with LVH at baseline, mean (95% CI) LVMI
(g/m2.7/year) had slight positive slopes throughout the 10-
year treatment period of +1.51 (+0.91, +2.12) for females
(n=18) and +0.87 (+0.19, +1.55) for males (n=14).
Stratification by baseline eGFR (Figure 6) showed that
in patients with baseline eGFR <60 mL/min/1.73 m2, the
mean (95% CI) slope (mm/year) of PWTD over the 10-
year treatment period was +0.01 (−0.12, +0.15) for
females (n=6) and +0.03 (−0.11, +0.18) for males (n=4).
Among those with baseline eGFR ≥60 mL/min/1.73 m2,
the mean (95% CI) slope was +0.10 (+0.01, +0.18) for
females (n=24) and +0.11 (+0.03, +0.19) for males (n=23).
Among cardiac cohort patients without renal involvement
(ie, eGFR >90 mL/min/1.73 m2 and urinary protein <0.5 g/
day) at baseline (6 of 34 [17.6%] females and 10 of 35
[28.6%] males), the mean (95% CI) LVMI measurements
(g/m2.7) at baseline and year 10, respectively, were 43.3
(27.1, 59.5) and 45.9 (22.9, 69.0) in females (n=6) and 39.3
(34.1, 44.5) and 43.2 (36.3, 50.1) in males (n=10; Figure 7).
Discussion
Our current analysis of a subset of the FOS population
showed that during 10 years of agalsidase alfa ERT, renal
function was relatively stable in females and showed mod-
est decreases in males; these observations should be con-
sidered in the context of the natural history of Fabry disease
as described in the literature. Schiffmann et al14 published a
retrospective chart review of 168 female and 279 male
untreated patients examined between 1944 and 2002 in






























































Figure 2 Mean (95% CI) eGFR MDRD (mL/min/1.73 m2) over a 10-year duration of
enzyme replacement therapy for female and male populations in the evaluable
treated renal cohort*. *Data shown are cross-sectional values.
Abbreviations: eGFR, estimated glomerular filtration rate; MDRD, Modification of
Diet in Renal Disease.
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third of these patients receiving angiotensin receptor block-
ers or angiotensin-converting enzyme inhibitors. Among
those with baseline eGFR <60 mL/min/1.73 m2 (calculated
from serum creatinine measurements with the abbreviated
Modification of Diet in Renal Disease [MDRD] equation),
the mean eGFR change was −2.1 and −6.8 mL/min/1.73
m2/year, respectively, in females and males. Among those
with baseline eGFR ≥60 mL/min/1.73 m2, the mean eGFR
change was −0.9 and −3.0 mL/min/1.73 m2/year, respec-
tively, in females and males. Male patients and those with
hypertension, baseline proteinuria, or impaired renal func-
tion at baseline had a more rapid loss of renal function.
A FOS analysis by Mehta et al of adults who received 5
years of agalsidase alfa showed mean annual eGFR changes
of −0.89 and −3.17 mL/min/1.73 m2 in females and males,
respectively.15 The authors noted these declines in eGFR
(calculated from serum creatinine measurements with the
MDRD equation) were slower than those reported for the
natural history of the disease and were similar to those
Figure 3 Individual profiles and average slope estimates for eGFR over time for the evaluable renal cohort (n=152) for the: (A) female population, baseline eGFR ≥60 mL/
min/1.73 m2; (B) female population, baseline eGFR <60 mL/min/1.73 m2; (C) male population, baseline eGFR ≥60 mL/min/1.73 m2; (D) male population, baseline eGFR <60
mL/min/1.73 m2. Full interaction model: [age] × [sex] × [baseline] category.




















































Figure 4 Mean (95% CI) LVMI (g/m2.7) over a 10-year duration of enzyme replace-
ment therapy for female and male populations in the evaluable treated cardiac
cohort*. *Data shown are cross-sectional values.
Abbreviations: LVMI, left ventricular mass index.
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expected with age in females and approximately 2 to 3
times greater than those expected with age in males.
Among the patients with baseline eGFR ≥130 mL/min/
1.73 m2, ~86% had eGFR within the normal range after 5
years of ERT, and among patients with baseline eGFR
classified as chronic kidney disease stages 1 to 3, mean
annual changes in eGFR were between −1.53 and −2.63
mL/min/1.73 m2, with renal function stabilization or
improvement in 56.5% to 75.0% of the patients, and slowed
decline of eGFR in 68.8% to 89.1%.
Nowak et al recently published results from prospec-
tive disease progression modeling of renal function in
adults with classical Fabry disease.16 During a median
follow-up of 9 years in 21 treated females and 24 treated
males (most received agalsidase alfa), female patients had
a stable renal function (eGFR slope, −0.07 mL/min/1.73
m2/year) and males had a change in eGFR of −3.07 mL/
min/1.73 m2/year. There was no clear effect of angiotensin
receptor blockers or angiotensin-converting enzyme inhi-
bitors on the eGFR slope, but there was an effect on
proteinuria. The effect of these medications on proteinuria
has been described in patients with various proteinuric
conditions;17,18 this is also expected in Fabry disease.
The effects of these medications on eGFR slope is less
consistent in the literature and may be related to protei-
nuria reduction rather than a direct effect of the medica-
tions. The patients in the Nowak report had a median
baseline eGFR of 92 mL/min/1.73 m2 in females and 96
mL/min/1.73 m2 in males (calculated using the serum
creatinine-based Chronic Kidney Disease-Epidemiology
Collaboration [CKD-EPI(cr)] equation);16 our FOS evalu-
able treated renal cohort had a mean baseline eGFR of
80.4 mL/min/1.73 m2 in females and 95.0 mL/min/1.73 m2
in males.
Germain et al published a 10-year analysis of patients
receiving agalsidase beta ERT stratified by baseline renal
involvement.3 The study included data collected from 50
males and 2 females enrolled in a phase 3 clinical trial and
an open-label extension study, as well as subsequent data
after the patients entered the Fabry Registry. Overall,
Figure 5 Individual profiles and average slope estimates for LVMI over time for the evaluable cardiac cohort (n=69) for the (A) female population, LVH at baseline; (B)
female population, no LVH at baseline; (C) male population, LVH at baseline; (D) male population, no LVH at baseline.
Abbreviations: LVH, left ventricular hypertrophy; LVMI, left ventricular mass index; SEM, standard error of the mean.
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patients in the Germain et al study were younger at treat-
ment start (mean age, 30.1 years) than those in our FOS
evaluable renal cohort (mean age, 40.2 years), and had a
higher eGFR (calculated using the serum creatinine-based
CKD-EPI(cr) equation) at baseline (mean, 116.6 mL/min/
1.73 m2) than patients in our FOS evaluable renal cohort
(mean, 89.0 mL/min/1.73 m2). Germain et al classified
patients as having low or high baseline renal involvement:
low renal involvement was defined by a urinary protein-to-
creatinine ratio of ≤0.5 g/g and <50% sclerotic glomeruli
in renal biopsies collected during the first 6 months of the
study, while high renal involvement was defined by a
urinary protein-to-creatinine ratio of >0.5 g/g or ≥50%
sclerotic glomeruli. The mean eGFR slope was −1.89
and −6.82 mL/min/1.73 m2/year over 10 years among
patients classified as having low (n=32) or high (n=20)
renal involvement, respectively, at baseline. We stratified
our FOS evaluable renal cohort by baseline eGFR ≥60 or
<60 mL/min/1.73 m2. In our analyses of those with higher
baseline eGFR, renal function was relatively stable (slope
Figure 6 Individual profiles and average slope estimates for left ventricular PWTD over time for the evaluable cardiac cohort (n=69) for the (A) female population, baseline
eGFR ≥60 mL/min/1.73 m2; (B) female population, baseline eGFR <60 mL/min/1.73 m2; (C) male population, baseline eGFR ≥60 mL/min/1.73 m2; (D) male population,
baseline eGFR <60 mL/min/1.73 m2.





















































Figure 7 Mean (95% CI) LVMI (g/m2.7) over a 10-year duration of enzyme replace-
ment therapy for female and male patients with baseline eGFR >90 mL/min/1.73 m2
and urinary protein <0.5 g/day in the evaluable treated cardiac cohort.
Abbreviations: eGFR, estimated glomerular filtration rate; LVMI, left ventricular
mass index.
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estimate, −0.55) in 52 females and showed modest
declines (slope estimate, −1.99) in 79 males over 10
years of ERT; our analysis of those with impaired renal
function at baseline showed a steady eGFR (slope esti-
mate, −0.14) in 10 females and a modest decline (slope
estimate, −2.79) in 11 males. Taken together, patients
treated with agalsidase alfa or beta over 10 years show
better preservation of renal function when ERT was started
with earlier kidney disease characterized by higher base-
line eGFR and less proteinuria.
Our current FOS analysis showed that during 10 years
of agalsidase alfa ERT, LVMI had relatively small
increases among patients with LVH at baseline and was
stable among patients without LVH at baseline. The
observed increases in LVMI were less than those reported
in an untreated population, in which LVMI was shown to
increase at a rate of 2.31 g/m2.7/year in females and
4.07 g/m2.7/year in males.13 In addition, patients without
renal involvement and LVH at baseline who received
agalsidase alfa ERT over 10 years in FOS had stable
cardio-renal outcomes, which would be beneficial in pre-
venting early organ manifestation of the disease. In a 10-
year analysis by Kampmann et al of patients receiving
agalsidase alfa at a single FOS site,19 males with baseline
LVMI ≥50 g/m2.7 had statistically significant reductions
in LVMI from baseline at years 1, 2, 3, 5, and 10, while
females had similar improvements in LVMI at years 1, 2,
and 3. Reflecting our findings, in patients with baseline
LVMI <50 g/m2.7, LVMI was not significantly changed
from baseline over 10 years of ERT.19 The patient popu-
lation, management, and follow-up in our current FOS
10-year multicenter analysis were less homogeneous than
in the single-center report by Kampmann et al, but our
overall treatment outcomes were similar and appear con-
sistent with the single-center experience.
Our current analysis also showed that over 10 years of
ERT, in patients with minimal renal involvement at base-
line, LVMI was stable over 10 years, between 43.3 and
45.9 g/m2.7 in females and between 39.3 and 43.2 g/m2.7 in
males. This finding is in agreement with the results
reported by Germain et al, in which the mean slopes of
left posterior wall thickness over 10 years of agalsidase
beta ERT were +0.08 mm/year and +0.10 mm/year in
patients with low and high Fabry disease renal involve-
ment, respectively, at baseline.3 Compared with the popu-
lation in the Germain et al report, our cohort had similar or
greater overall disease severity at baseline.
Several limitations of our study should be considered.
Observational studies, including analysis of patient registry
data, provide important real-world evidence that complements
the limited information available from randomized controlled
trials in rare diseases. However, with registry data in general, it
is difficult to ensure comprehensive data capture, assessments
may not be standardized across multiple sites, and there is the
possibility of patient enrollment bias as patients with more
severe symptoms or who are receiving treatment are more
likely to be enrolled in a registry. This retrospective analysis
of 10-year FOS patient registry data did not include compar-
isons with untreated patients from the same registry because
there were too few untreated patients to match by sex, age,
and/or disease severity. The patients in the FOS registry were
not randomly selected, possibly giving rise to selection and/or
ascertainment bias. For example, male patients may have been
identified and treated earlier than females, whereas treatment
start may have in some cases been delayed in females until
organ involvement was established (as suggested by lower
eGFR at baseline). Although the serum creatinine-based
CKD-EPI(cr) equation may provide a more accurate estima-
tion at eGFR >60 mL/min/1.73 m2, the MDRD equation is
widely used,20 allowing comparison with more studies, and
was used in the FOS 5-year analysis. However, proteinuria and
its effect on eGFR slopes were also not fully investigated in
this analysis. There was no centralized reading of echocardio-
grams in the FOS cohorts. There is the possibility of bias
associated with the censoring of patients who stopped agalsi-
dase alfa treatment. The relatively small sample size, espe-
cially in subgroups, could affect the precision and robustness
of estimates, and the lack of data regarding Fabry disease
phenotype, proteinuria, and blood pressure control may limit
the generalizability of our observations. The relationship of the
surrogate endpoints in this analysis to clinical endpoints is not
clear. By the nature of the analysis, the clinical endpoints may
be enriched in people who died or stopped ERT.
Conclusion
The current analysis of a cohort of FOS provides evidence
supporting the benefits of agalsidase alfa ERT over 10
years. Patients with preserved kidney function and/or nor-
mal LVMI at baseline remained largely stable during 10
years of ERT, whereas those patients with reduced eGFR
and/or evidence of LVH at baseline experienced modest
declines in renal function and/or increases in LVMI that
were less than expected based on natural history data. These
findings suggest that early treatment, before substantial
organ damage has occurred, may improve outcomes.
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